Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing small-molecule therapies designed to modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations, with the aim of restoring full-length proteins in genetic diseases. Its lead… From the company’s description.
In fiscal 2025, Eloxx Pharmaceuticals, Inc. reported a net loss of $6.00M. Operations used $6.33M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What Eloxx Pharmaceuticals, Inc. does
In the company’s own words
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing small-molecule therapies designed to modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations, with the aim of restoring full-length proteins in genetic diseases. Its lead candidate, exaluren, is being developed for Alport syndrome with nonsense mutations and is also in preclinical development for autosomal dominant polycystic kidney disease; the company’s pipeline includes ZKN-013 for rare skin diseases. Eloxx collaborates with Almirall, which holds global development and commercialization rights to ZKN-013 for orphan dermatological diseases, including recessive dystrophic and junctional epidermolysis bullosa. The company’s activities focus on research and development rather than commercial product sales. Its primary program is exaluren, while ZKN-013 is advanced through the Almirall collaboration. As of December 31, 2025, Eloxx owned or licensed 66 issued patents and 101 pending patent applications in the United States and abroad. Its website is www.eloxxpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- ARLINGTON, MA
- Fiscal year end
- December
- CIK
- 1035354
- SIC
- 2836
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Eloxx Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Eloxx Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Eloxx Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Eloxx Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Eloxx Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”